Prognostic significance of various 11q23/KMT2A rearrangements in infants with acute lymphoblastic leuekemia

The purpose of this work was evaluation prognostic significance 11q23/KMT2A rearrangements in infants (aged under 365 days) with B-cell precursor acute lymphoblastic leukemia (ALL) enrolled Russian-Belarus multicenter trial MLLBaby. This study is supported by the Independent Ethics Committee and approved Academic Council Research Institute Medical Cell Technologies (Ekaterinburg). Various were revealed 100 (72%) 139 patients. Event-free survival (EFS) intermediate risk group MLL-Baby 35.1% (standard error (SE) 6.9%), high – 38.3% (SE 7.1%) (p = 0.941). most unfavorable prognosis had translocation t(9;11)/KMT2A-MLLT3: EFS 18.8% 9.8%), cumulative incidence relapse (CIR) 75.0% 9.7%). Intermediate results obtained patients translocations t(4;11)/KMT2A-AFF1 t(11;19)/KMT2A-MLLT1: 36.9% 7,2%) 32,7% 10.4%), respectively; CIR 46.3% 7.8%) 50.9% 12.3%). favorable treatment outcome achieved carrying t(10;11)(p12;q23)/KMT2A-MLLT10: 83.3% 15.2%), 0,0%. In multivariate analysis KMT2A-rearranged infant ALL associated initial CNS involvement 0.020), white blood cell count higher than 300 × 109 /L 0.028), more 5% blast cells on day 15 bone marrow 0.012) presence t(11;19)/KMT2A-MLLT1 0.012).